Son of a Lesser God: The Case of Cell Therapy for Refractory Angina

Front Cardiovasc Med

27 Settembre Set 2021 one month ago
  • Bassetti B, Rurali E, Gambini E, Pompilio G

In the last decades, various non-pharmacological solutions have been tested on top of medical therapy for the treatment of patients affected by refractory angina (RA). Among these therapeutics, neuromodulation, external counter-pulsation and coronary sinus constriction have been recently introduced in the guidelines for the management of RA in United States and Europe. Notably and paradoxically, although a consistent body of evidence has proposed cell-based therapies (CT) as safe and salutary for RA outcome, CT has not been conversely incorporated into current international guidelines yet. As a matter of fact, published randomized controlled trials (RCT) and meta-analyses (MTA) cumulatively indicated that CT can effectively increase perfusion, physical function and well-being, thus reducing angina symptoms and drug assumption in RA patients. In this review, we (i) provide an updated overview of novel non-pharmacological therapeutics included in current guidelines for the management of patients with RA, (ii) discuss the Level of Evidence stemmed from available clinical trials for each recommended treatment, and (iii) focus on evidence-based CT application for the management of RA.

Reference

Son of a Lesser God: The Case of Cell Therapy for Refractory Angina. Bassetti B, Rurali E, Gambini E, Pompilio G. Front Cardiovasc Med. 2021 Sep 6;8:709795. doi: 10.3389/fcvm.2021.709795. eCollection 2021

Go to PubMed